Andrew Tutt
A5087121536- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Bioinformatics and Genomic Networks
- Computational Drug Discovery Methods
- CRISPR and Genetic Engineering
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
- Cancer-related Molecular Pathways
- Radiopharmaceutical Chemistry and Applications
- Microtubule and mitosis dynamics
- Cell Adhesion Molecules Research
- Gene expression and cancer classification
- RNA modifications and cancer
- Genetics, Bioinformatics, and Biomedical Research
- Epigenetics and DNA Methylation
Breast Cancer Now
2016-2025
Institute of Cancer Research
2016-2025
King's College London
2015-2024
Response Biomedical (Canada)
2024
Target (United States)
2024
Dana-Farber Cancer Institute
2009-2023
Guy's Hospital
2014-2023
Guy's and St Thomas' NHS Foundation Trust
2003-2023
Breast International Group
2023
London Cancer
2018-2023
The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment cancers with specific DNA-repair defects, including those arising in carriers BRCA1 or BRCA2 mutation. We conducted clinical evaluation humans olaparib (AZD2281), novel, potent, orally active PARP inhibitor.This was phase 1 trial that included analysis pharmacokinetic and pharmacodynamic characteristics olaparib. Selection aimed at having study...
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Abstract Deficiency in either of the breast cancer susceptibility proteins BRCA1 or BRCA2 induces profound cellular sensitivity to inhibition poly(ADP-ribose) polymerase (PARP) activity. We hypothesized that critical role and repair double-strand breaks by homologous recombination (HR) was underlying reason for this sensitivity. Here, we examine effects deficiency several involved HR on PARP inhibition. show RAD51, RAD54, DSS1, RPA1, NBS1, ATR, ATM, CHK1, CHK2, FANCD2, FANCA, FANCC such This...
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers whom cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR repair capacity. Olaparib is potent, oral PARP that well tolerated, antitumor activity carriers. Patients and Methods BRCA1/2-mutated ovarian cancer were treated olaparib within...
Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in approximately 10% breast cancers and is associated with poor prognosis. However, it uncertain whether overexpression FGFR1 causally linked to the prognosis amplified cancers. Here, we show that robustly amplification two independent series Breast cancer cell lines enhanced ligand-dependent signaling, increased activation mitogen-activated protein kinase phosphoinositide 3-kinase-AKT signaling pathways response FGF2, but...
Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with having dismal survival. We sequenced whole genomes or a panel 365 genes on 299 samples from 170 locally relapsed cancer. Several lines analysis indicate that clones seeding metastasis relapse disseminate late tumors, but continue to acquire mutations, mostly accessing the same mutational processes active tumor. Most distant metastases acquired driver...